StockMacro
Company, fund or insider

Help

Menu

Corcept Therapeutics

$63.62 +5.4% in 6 monthsMarket cap $6.9B

CORT on XNAS, Health Care, Corcept Therapeutics Inc., job postings

Measures activity, not value. Not investment advice.

Quarterly revenue rose 64% to $340.5M but the stock fell 45% in a month while insiders sold $28.5M.

  • GoodInstitutional holders rose 20% to 497 in the latest quarter
  • BadShort interest rose 6.3% on the prior report, to 8.3% of shares

Written by AI from the data on this page, 21 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.

Industry
Pharmaceutical preparations (Health Care)
Employees
730
Website
corcept.com
Listed
Nasdaq, US
Last results
3 Nov 2026
Next results
expected around 23 Feb 2027 (an estimate: a year ago it reported on 24 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $340.5M, net income $126.8M.
Quarter to 31 Dec 2021: revenue $98.8M, net income $32.1MQuarter to 31 Dec 2021: revenue $98.8M, net income $32.1MQuarter to 31 Mar 2022: revenue $93.7M, net income $22.8MQuarter to 31 Mar 2022: revenue $93.7M, net income $22.8MQuarter to 30 Jun 2022: revenue $103.4M, net income $27.4MQuarter to 30 Jun 2022: revenue $103.4M, net income $27.4MQuarter to 30 Sep 2022: revenue $101.7M, net income $34.6MQuarter to 30 Sep 2022: revenue $101.7M, net income $34.6MQuarter to 31 Dec 2022: revenue $103.1M, net income $16.6MQuarter to 31 Dec 2022: revenue $103.1M, net income $16.6MQuarter to 31 Mar 2023: revenue $105.7M, net income $15.9MQuarter to 31 Mar 2023: revenue $105.7M, net income $15.9MQuarter to 30 Jun 2023: revenue $117.7M, net income $27.5MQuarter to 30 Jun 2023: revenue $117.7M, net income $27.5MQuarter to 30 Sep 2023: revenue $123.6M, net income $31.4MQuarter to 30 Sep 2023: revenue $123.6M, net income $31.4MQuarter to 31 Dec 2023: revenue $135.4M, net income $31.4MQuarter to 31 Dec 2023: revenue $135.4M, net income $31.4MQuarter to 31 Mar 2024: revenue $146.8M, net income $27.8MQuarter to 31 Mar 2024: revenue $146.8M, net income $27.8MQuarter to 30 Jun 2024: revenue $163.8M, net income $35.5MQuarter to 30 Jun 2024: revenue $163.8M, net income $35.5MQuarter to 30 Sep 2024: revenue $182.5M, net income $47.2MQuarter to 30 Sep 2024: revenue $182.5M, net income $47.2MQuarter to 31 Dec 2024: revenue $181.9M, net income $30.7MQuarter to 31 Dec 2024: revenue $181.9M, net income $30.7MQuarter to 31 Mar 2025: revenue $157.2M, net income $20.5MQuarter to 31 Mar 2025: revenue $157.2M, net income $20.5MQuarter to 30 Jun 2025: revenue $194.4M, net income $35.1MQuarter to 30 Jun 2025: revenue $194.4M, net income $35.1MQuarter to 30 Sep 2025: revenue $207.6M, net income $19.7MQuarter to 30 Sep 2025: revenue $207.6M, net income $19.7MQuarter to 31 Dec 2025: revenue $202.1M, net income $24.3MQuarter to 31 Dec 2025: revenue $202.1M, net income $24.3MQuarter to 31 Mar 2026: revenue $164.9M, net income -$31.8MQuarter to 31 Mar 2026: revenue $164.9M, net income -$31.8MQuarter to 30 Jun 2026: revenue $256.1M, net income $43.0MQuarter to 30 Jun 2026: revenue $256.1M, net income $43.0MQuarter to 30 Sep 2026: revenue $340.5M, net income $126.8MQuarter to 30 Sep 2026: revenue $340.5M, net income $126.8M
31 Dec 2021RevenueNet incomeNet losstallest bar $340.5M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$340.5M$126.8M
30 Jun 2026$256.1M$43.0M
31 Mar 2026$164.9M-$31.8M
31 Dec 2025$202.1M$24.3M
30 Sep 2025$207.6M$19.7M
30 Jun 2025$194.4M$35.1M
31 Mar 2025$157.2M$20.5M
31 Dec 2024$181.9M$30.7M
30 Sep 2024$182.5M$47.2M
30 Jun 2024$163.8M$35.5M
31 Mar 2024$146.8M$27.8M
31 Dec 2023$135.4M$31.4M
30 Sep 2023$123.6M$31.4M
30 Jun 2023$117.7M$27.5M
31 Mar 2023$105.7M$15.9M
31 Dec 2022$103.1M$16.6M
30 Sep 2022$101.7M$34.6M
30 Jun 2022$103.4M$27.4M
31 Mar 2022$93.7M$22.8M
31 Dec 2021$98.8M$32.1M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $963.6M $741.2M
Revenue growthRevenue of the last 12 months compared with the 12 months before. +30% +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $162.3M $106.1M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). $1.27 $0.87
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 98.5% 98.2% 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. 11.5% 8.8% -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. 16.8% 14.3% -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. 22.1% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $370.7M $421.7M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$370.7M (net cash) -$421.7M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $7.62
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. 42.9 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. 7.2 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 6.8 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 8.4 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Corcept TherapeuticsCORT (this company) $6.9B42.97.2+30%16.8%
Axsome TherapeuticsAXSM $6.8Bloss7.9+54%-18.2%
CytokineticsCYTK $7.1Bloss62.4+30%-687%
Oruka TherapeuticsORKA $6.5Bloss–––
Amneal PharmaceuticalsAMRX $7.4B55.22.3+8.9%4.2%
Kiniksa Pharmaceuticals InternationalKNSA $7.4B67.37.8+58%11.6%

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+64%

$340.5M vs $207.6M (quarter ended 30 Sep 2026)

Insider buy/sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$28.5M

bought $0, sold $28.5M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+20%

497 13F filers vs 414

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

73%

80.0M shares held by 13F filers (30 Sep 2026) of 109.4M outstanding (22 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

8.3%

9.1M shares sold short (30 Oct 2026) of 109.4M outstanding (22 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

8.1

9.1M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+6.3%

8.6M shares sold short in the report before, 9.1M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

56%

56% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 64%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

59

Tracked since 20 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 20 Nov 2026; the change shows after 30 days.

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

15

15 articles in the last 7 days; its usual week has 5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

3.0×

15 articles in the last 7 days; its usual week has 5.

Unusual now sharp changes in the last 90 days, compared with its own past

  • Revenue $340.5M, 1.6× a year earlier
  • New institutional positions 117, 2.2× a year earlier

Price $63.62 on 20 Nov 2026, -15% over 12 months (12-month range $32.15 to $123.57)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders sold a net $94.7M in the last 12 months (the 12 months before: -$89.7M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 3 published in the last 12 months, -40% on the 12 months before.
Revenue per quarter. Revenue $340.5M in the latest quarter, +64% on a year earlier.
Capital spending per quarter. Capital spending $709K in the latest quarter.
Institutional holders (13F filers). 497 13F filers reported holding it in the latest 13F quarter, +23% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
17 Nov 2026Sharp changeMany funds opening a new position: many funds opening a new position, 117 vs usual 59.50 (2026-09-30); 2.2x the same period a year earlier
5 Nov 2026Sharp changeQuarterly revenue change: quarterly revenue change, 340.5M vs usual 188.5M (2026-09-30); 1.6x the same period a year earlier
23 Sep 20268-K and other filingsDirector or officer change
23 Sep 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
28 May 20268-K and other filingsDirector or officer change
28 May 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
14 Oct 20258-K and other filingsA major agreement ended
6 Oct 20258-K and other filingsDirector or officer change
6 Oct 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
15 May 2025Sharp changeMany funds opening a new position: many funds opening a new position, 88 vs usual 37 (2025-03-31); 1.9x the same period a year earlier
19 Nov 2024Sharp changeMany funds opening a new position: many funds opening a new position, 50 vs usual 32 (2024-09-30); 1.6x the same period a year earlier
30 Jul 2024Sharp changeQuarterly revenue change: quarterly revenue change, 163.8M vs usual 111.7M (2024-06-30); 1.4x the same period a year earlier
16 Jul 2024Sharp changeShort interest spike: short interest spike, 21.9M vs usual 15.7M (2024-06-28); 1.4x the same period a year earlier
2 Jul 2024Sharp changeShort interest spike: short interest spike, 21.2M vs usual 15.7M (2024-06-14); 1.3x the same period a year earlier
23 May 20248-K and other filingsDirector or officer change
23 May 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
21 May 2024Sharp changeMany funds opening a new position: many funds opening a new position, 47 vs usual 31.50 (2024-03-31); 1.5x the same period a year earlier
7 May 2024Sharp changeQuarterly revenue change: quarterly revenue change, 146.8M vs usual 104.5M (2024-03-31); 1.4x the same period a year earlier
16 Apr 2024Sharp changeShort interest spike: short interest spike, 21.3M vs usual 15.7M (2024-03-28); 1.2x the same period a year earlier
20 Feb 2024Sharp changeQuarterly revenue change: quarterly revenue change, 135.4M vs usual 103.2M (2023-12-31); 1.3x the same period a year earlier
20 Feb 2024Sharp changeMany funds opening a new position: many funds opening a new position, 42 vs usual 31 (2023-12-31); 1.3x the same period a year earlier
31 May 2022Sharp changeShort interest spike: short interest spike, 20.3M vs usual 9.9M (2022-05-13); 2.1x the same period a year earlier
15 Mar 2022Sharp changeShort interest spike: short interest spike, 16.2M vs usual 9.9M (2022-02-28); 1.5x the same period a year earlier
1 Mar 2022Sharp changeShort interest spike: short interest spike, 16.3M vs usual 9.9M (2022-02-15); 1.5x the same period a year earlier
15 Feb 2022Sharp changeShort interest spike: short interest spike, 18.2M vs usual 9.9M (2022-01-31); 1.6x the same period a year earlier
1 Feb 2022Sharp changeShort interest spike: short interest spike, 19.2M vs usual 9.9M (2022-01-14); 1.6x the same period a year earlier
28 Dec 2021Sharp changeShort interest spike: short interest spike, 19.4M vs usual 9.9M (2021-12-15); 1.5x the same period a year earlier
Insider net buying (open market)
Month from 1 Mar 2022: -$308K published
Month from 1 May 2022: -$684K published
Month from 1 Jul 2022: -$10.7M published
Month from 1 Aug 2022: -$441K published
Month from 1 Sep 2022: -$1.9M published
Month from 1 Oct 2022: -$641K published
Month from 1 Nov 2022: -$1.4M published
Month from 1 Dec 2022: -$16K published
Month from 1 May 2023: -$1.1M published
Month from 1 Jun 2023: -$236K published
Month from 1 Aug 2023: -$1.6M published
Month from 1 Sep 2023: -$1.3M published
Month from 1 Oct 2023: -$878K published
Month from 1 Nov 2023: -$905K published
Month from 1 Dec 2023: -$1.3M published
Month from 1 Jan 2024: -$49K published
Month from 1 Feb 2024: -$896K published
Month from 1 Mar 2024: -$1.1M published
Month from 1 Apr 2024: -$210K published
Month from 1 May 2024: -$3.2M published
Month from 1 Jun 2024: -$537K published
Month from 1 Jul 2024: -$917K published
Month from 1 Aug 2024: -$503K published
Month from 1 Sep 2024: -$353K published
Month from 1 Oct 2024: -$972K published
Month from 1 Nov 2024: -$848K published
Month from 1 Dec 2024: -$131K published
Month from 1 Jan 2025: -$1.9M published
Month from 1 Feb 2025: -$1.8M published
Month from 1 Mar 2025: -$3.1M published
Month from 1 Apr 2025: -$33.9M published
Month from 1 May 2025: -$11.7M published
Month from 1 Jun 2025: -$7.1M published
Month from 1 Jul 2025: -$1.2M published
Month from 1 Aug 2025: -$8.3M published
Month from 1 Sep 2025: -$6.2M published
Month from 1 Oct 2025: -$7.5M published
Month from 1 Nov 2025: -$6.7M published
Month from 1 Dec 2025: -$6.8M published
Month from 1 Jan 2026: -$704K published
Month from 1 Feb 2026: -$817K published
Month from 1 Mar 2026: $1.3M published
Month from 1 Apr 2026: -$819K published
Month from 1 May 2026: -$8.3M published
Month from 1 Jun 2026: -$12.6M published
Month from 1 Jul 2026: -$8.5M published
Month from 1 Aug 2026: -$36.2M published
Month from 1 Sep 2026: -$11.6M published
Month from 1 Oct 2026: -$6.2M published
Month from 1 Nov 2026: -$3.6M published
H-1B/E-3 applications certified
Quarter from 1 Apr 2022: 1 published
Quarter from 1 Jul 2022: 1 published
Quarter from 1 Oct 2022: 1 published
Quarter from 1 Apr 2023: 1 published
Quarter from 1 Jul 2023: 1 published
Quarter from 1 Oct 2023: 2 published
Quarter from 1 Oct 2024: 4 published
Quarter from 1 Jan 2025: 2 published
Quarter from 1 Jul 2025: 1 published
Quarter from 1 Oct 2025: 2 published
Quarter from 1 Jan 2026: 1 published
Quarter from 1 Apr 2026: 1 published
Quarter from 1 Oct 2026: 1 published
Revenue per quarter
Quarter ended 31 Dec 2021: $98.8M, +15% on a year earlier; public on 16 Feb 2022
Quarter ended 31 Mar 2022: $93.7M, +18% on a year earlier; public on 6 May 2022
Quarter ended 30 Jun 2022: $103.4M, +13% on a year earlier; public on 5 Aug 2022
Quarter ended 30 Sep 2022: $101.7M, +5.8% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $103.1M, +4.3% on a year earlier; public on 1 Mar 2023
Quarter ended 31 Mar 2023: $105.7M, +13% on a year earlier; public on 4 May 2023
Quarter ended 30 Jun 2023: $117.7M, +14% on a year earlier; public on 3 Aug 2023
Quarter ended 30 Sep 2023: $123.6M, +22% on a year earlier; public on 2 Nov 2023
Quarter ended 31 Dec 2023: $135.4M, +31% on a year earlier; public on 16 Feb 2024
Quarter ended 31 Mar 2024: $146.8M, +39% on a year earlier; public on 2 May 2024
Quarter ended 30 Jun 2024: $163.8M, +39% on a year earlier; public on 30 Jul 2024
Quarter ended 30 Sep 2024: $182.5M, +48% on a year earlier; public on 31 Oct 2024
Quarter ended 31 Dec 2024: $181.9M, +34% on a year earlier; public on 27 Feb 2025
Quarter ended 31 Mar 2025: $157.2M, +7.1% on a year earlier; public on 6 May 2025
Quarter ended 30 Jun 2025: $194.4M, +19% on a year earlier; public on 1 Aug 2025
Quarter ended 30 Sep 2025: $207.6M, +14% on a year earlier; public on 5 Nov 2025
Quarter ended 31 Dec 2025: $202.1M, +11% on a year earlier; public on 25 Feb 2026
Quarter ended 31 Mar 2026: $164.9M, +4.9% on a year earlier; public on 1 May 2026
Quarter ended 30 Jun 2026: $256.1M, +32% on a year earlier; public on 30 Jul 2026
Quarter ended 30 Sep 2026: $340.5M, +64% on a year earlier; public on 4 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $65K, -85% on a year earlier; public on 16 Feb 2022
Quarter ended 31 Mar 2022: $12K, -90% on a year earlier; public on 6 May 2022
Quarter ended 30 Jun 2022: $19K, -84% on a year earlier; public on 5 Aug 2022
Quarter ended 30 Sep 2022: $351K, +121% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $31K, -52% on a year earlier; public on 1 Mar 2023
Quarter ended 31 Mar 2023: $0, -100% on a year earlier; public on 4 May 2023
Quarter ended 30 Jun 2023: $102K, +437% on a year earlier; public on 3 Aug 2023
Quarter ended 30 Sep 2023: $37K, -89% on a year earlier; public on 2 Nov 2023
Quarter ended 31 Mar 2024: $0; public on 6 May 2025
Quarter ended 30 Jun 2024: $416K, +308% on a year earlier; public on 30 Jul 2024
Quarter ended 30 Sep 2024: $1.6M, +4319% on a year earlier; public on 31 Oct 2024
Quarter ended 31 Dec 2024: $121K; public on 27 Feb 2025
Quarter ended 31 Mar 2025: $104K; public on 6 May 2025
Quarter ended 30 Jun 2025: $57K, -86% on a year earlier; public on 1 Aug 2025
Quarter ended 31 Dec 2025: $50K, -59% on a year earlier; public on 25 Feb 2026
Quarter ended 31 Mar 2026: $201K, +93% on a year earlier; public on 1 May 2026
Quarter ended 30 Sep 2026: $709K; public on 4 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 193; public on 14 Feb 2022
31 Mar 2022 report: 212; public on 16 May 2022
30 Jun 2022 report: 209; public on 15 Aug 2022
30 Sep 2022 report: 214; public on 14 Nov 2022
31 Dec 2022 report: 222; public on 14 Feb 2023
31 Mar 2023 report: 216; public on 15 May 2023
30 Jun 2023 report: 204; public on 14 Aug 2023
30 Sep 2023 report: 224; public on 14 Nov 2023
31 Dec 2023 report: 260; public on 14 Feb 2024
31 Mar 2024 report: 271; public on 15 May 2024
30 Jun 2024 report: 268; public on 14 Aug 2024
30 Sep 2024 report: 300; public on 14 Nov 2024
31 Dec 2024 report: 356; public on 14 Feb 2025
31 Mar 2025 report: 398; public on 15 May 2025
30 Jun 2025 report: 401; public on 14 Aug 2025
30 Sep 2025 report: 404; public on 14 Nov 2025
31 Dec 2025 report: 370; public on 17 Feb 2026
31 Mar 2026 report: 339; public on 15 May 2026
30 Jun 2026 report: 414; public on 14 Aug 2026
30 Sep 2026 report: 497; public on 16 Nov 2026

What is unusual now

  • Made public in the last 90 days: it reported revenue of $340.5M for the quarter ended 30 Sep 2026, 1.6× the same quarter last year; it also saw 117 13F filers open a new position in the quarter ended 30 Sep 2026, 2.2× the same quarter last year. Two or more unrelated kinds of activity agreed on 17 Nov 2026.
  • Quarterly revenue change: reported revenue of $340.5M for the quarter ended 30 Sep 2026, 1.6× the same quarter last year Public on 5 Nov 2026.
  • Many funds opening a new position: saw 117 13F filers open a new position in the quarter ended 30 Sep 2026, 2.2× the same quarter last year Public on 16 Nov 2026.
  • Insider net buying (open market): Insiders sold a net $94.7M in the last 12 months (the 12 months before: -$89.7M).

Latest records

The names and amounts behind the totals, newest first

Last 90 days: 15 sales, $28.5M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
17 Nov 2026James N WilsonDirectorSellplanned in advance (10b5-1)10,000$72.67$727KForm 4
13 Nov 2026Daniel N Swisher JrDirectorSellplanned in advance (10b5-1); after exercising options1,500$74.07$111KForm 4
4 Nov 2026Sean MaduckSee RemarksSellplanned in advance (10b5-1); after exercising options25,000$81.85$2.0MForm 4
4 Nov 2026Roberto Wandenkolk VieiraPresident, OncologySellplanned in advance (10b5-1); after exercising options8,333$80.89$674KForm 4
16 Oct 2026James N WilsonDirectorSellplanned in advance (10b5-1)10,000$114.81$1.1MForm 4
5 Oct 2026Roberto Wandenkolk VieiraPresident, OncologySellplanned in advance (10b5-1); after exercising options8,333$116.10$967KForm 4
5 Oct 2026Joseph Douglas LyonSee RemarksSellplanned in advance (10b5-1); after exercising options10,000$116.07$1.2MForm 4
5 Oct 2026Sean MaduckSee RemarksSellplanned in advance (10b5-1); after exercising options25,000$116.26$2.9MForm 4

497 institutions reported shares at the end of Q3 2026, 73% of the shares outstanding; 116 opened a position, 33 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
BlackRock, Inc.10.2M9.32%$1.2B-2.2M-18%
Ingalls & Snyder LLC7.7M7.01%-267K-3.4%
Renaissance Technologies LLC4.9M4.43%$558.9M-412K-7.8%
Vanguard Portfolio Management LLC4.8M4.36%$550.5M-268K-5.3%
Vanguard Capital Management LLC4.4M3.98%$501.6M+181K+4.3%
Parallel Advisors, LLC3.9M3.57%$449.7M-60K-1.5%
AQR Capital Management LLC3.6M3.33%$419.5M+1.1M+41%
FMR LLC (Fidelity)3.5M3.19%$402.0M+151K+4.5%
State Street Corp3.1M2.84%$357.8M-174K-5.3%
Geode Capital Management, LLC2.3M2.13%$269.2M-197K-7.8%

Company events

All 18 company events

In 12 months: 2 director or officer changes. Results releases and routine reports are left out.

FiledWhat happenedSource
23 Sep 2026Director or officer change8-K
28 May 2026Director or officer changeSame filing: shareholder vote results8-K
14 Oct 2025A major agreement ended8-K
6 Oct 2025Director or officer change8-K
23 May 2024Director or officer changeSame filing: shareholder vote results8-K
17 Apr 2024Signed a major agreementSame filing: took on new debt8-K
22 Sep 2022Signed a major agreement8-K
12 Aug 2021Director or officer change8-K

59 open postings; careers site tracked since 20 Nov 2026. Most in Sales & business development 25%, Research & science 15%, Legal, policy & compliance 10%, Finance & accounting 8%.

PostedJobLocation
20 Nov 2026Clinical Sales Specialist (CS) - Fort Worth, TXSales & business developmentFort Worth, Texas, United States
19 Nov 2026Key Account Manager (KAM) - Central PlainsSales & business developmentUnited States
19 Nov 2026Key Account Manager (KAM) - Pacific NorthwestSales & business developmentUnited States
19 Nov 2026Associate Director, Clinical Records (eTMF)Research & scienceRedwood City, California, United States
19 Nov 2026Associate Director, Statistical ProgrammingResearch & scienceRedwood City, California, United States
14 Nov 2026Contracts Manager X 3Legal, policy & complianceRedwood City, California, United States
10 Nov 2026Senior Manager, Oncology Marketing OperationsMarketing & communicationsUnited States
10 Nov 2026Senior Manager, Oncology Marketing OperationsMarketing & communicationsRedwood City, California, United States

The 5 newest of 245 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

17 Nov 2026confirmed

Confirmed across sources Institutional holdings and Filings + Financials

Corcept Therapeutics (CORT): reported revenue of $340.5M for the quarter ended 30 Sep 2026, 1.6× the same quarter last year, while it saw 117 13F filers open a new position in the quarter ended 30 Sep 2026, 2.2× the same quarter last year. Two unrelated kinds of activity within 12 days.

  • Financials: Quarterly revenue change, became public on 5 Nov 2026
  • Institutional holdings: Many funds opening a new position, became public on 16 Nov 2026
2024-09-30: $182.5M2024-12-31: $181.9M2025-03-31: $157.2M2025-06-30: $194.4M2025-09-30: $207.6M2025-12-31: $202.1M2026-03-31: $164.9M2026-06-30: $256.1M2026-09-30: $340.5M
The quarter ended 30 Sep 2026 against the 8 quarters before it. this quarterearliernormal: $188.5M
See the evidence (2 changes)

Financials: Quarterly revenue change became public on 5 Nov 2026

Corcept Therapeutics reported revenue of $340.5M for the quarter ended 30 Sep 2026, 1.6× the same quarter last year.

This period
$340.5M (the quarter ended 30 Sep 2026)
Normal quarter (median of 8 earlier)
$188.5M
Typical spread (median absolute deviation)
$16.4M
How far from its usual level
+6.3
Same quarter last year
$207.6M
History used
3,835 days
2024-09-30: $182.5M2024-12-31: $181.9M2025-03-31: $157.2M2025-06-30: $194.4M2025-09-30: $207.6M2025-12-31: $202.1M2026-03-31: $164.9M2026-06-30: $256.1M2026-09-30: $340.5M
the quarter ended 30 Sep 20268 earlier quartersnormal: $188.5M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Institutional holdings: Many funds opening a new position became public on 16 Nov 2026

Corcept Therapeutics saw 117 13F filers open a new position in the quarter ended 30 Sep 2026, 2.2× the same quarter last year.

This period
117 (the quarter ended 30 Sep 2026)
Normal quarter (median of 8 earlier)
59.5
Typical spread (median absolute deviation)
7.5
How far from its usual level
+5.2
Same quarter last year
54
History used
4,748 days
2024-09-30: 502024-12-31: 622025-03-31: 882025-06-30: 632025-09-30: 542025-12-31: 432026-03-31: 572026-06-30: 1172026-09-30: 117
the quarter ended 30 Sep 20268 earlier quartersnormal: 59.5

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

30 Jul 2024confirmed

Confirmed across sources Filings + Financials and Short interest and volume

Corcept Therapeutics (CORT): had 21.9M shares sold short in the 28 Jun 2024 report, 1.4× the same report last year, while it reported revenue of $163.8M for the quarter ended 30 Jun 2024, 1.4× the same quarter last year. Two unrelated kinds of activity within 28 days.

  • Short interest and volume: Short interest spike, became public on 27 Jun 2024
  • Short interest and volume: Short interest spike, became public on 11 Jul 2024
  • Financials: Quarterly revenue change, became public on 30 Jul 2024
2023-06-30: 15.9M2023-07-14: 15.7M2023-07-31: 15.1M2023-08-15: 14.9M2023-08-31: 14.8M2023-09-15: 14.5M2023-09-29: 15.0M2023-10-13: 15.0M2023-10-31: 14.1M2023-11-15: 15.3M2023-11-30: 15.4M2023-12-15: 15.3M2023-12-29: 15.4M2024-01-12: 15.7M2024-01-31: 19.3M2024-02-15: 19.6M2024-02-29: 19.9M2024-03-15: 20.2M2024-03-28: 21.3M2024-04-15: 21.1M2024-04-30: 19.8M2024-05-15: 19.8M2024-05-31: 19.3M2024-06-14: 21.2M2024-06-28: 21.9M
The 28 Jun 2024 report against the 24 reports before it. this reportearliernormal: 15.7M
See the evidence (3 changes)

Short interest and volume: Short interest spike became public on 27 Jun 2024

Corcept Therapeutics had 21.2M shares sold short in the 14 Jun 2024 report, 1.3× the same report last year.

This period
21.2M (the 14 Jun 2024 report)
Normal report (median of 24 earlier)
15.7M
Typical spread (median absolute deviation)
988K
How far from its usual level
+3.5
Same report last year
16.8M
History used
2,359 days
2023-06-15: 16.8M2023-06-30: 15.9M2023-07-14: 15.7M2023-07-31: 15.1M2023-08-15: 14.9M2023-08-31: 14.8M2023-09-15: 14.5M2023-09-29: 15.0M2023-10-13: 15.0M2023-10-31: 14.1M2023-11-15: 15.3M2023-11-30: 15.4M2023-12-15: 15.3M2023-12-29: 15.4M2024-01-12: 15.7M2024-01-31: 19.3M2024-02-15: 19.6M2024-02-29: 19.9M2024-03-15: 20.2M2024-03-28: 21.3M2024-04-15: 21.1M2024-04-30: 19.8M2024-05-15: 19.8M2024-05-31: 19.3M2024-06-14: 21.2M
the 14 Jun 2024 report24 earlier reportsnormal: 15.7M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 11 Jul 2024

Corcept Therapeutics had 21.9M shares sold short in the 28 Jun 2024 report, 1.4× the same report last year.

This period
21.9M (the 28 Jun 2024 report)
Normal report (median of 24 earlier)
15.7M
Typical spread (median absolute deviation)
1.1M
How far from its usual level
+3.9
Same report last year
15.9M
History used
2,373 days
2023-06-30: 15.9M2023-07-14: 15.7M2023-07-31: 15.1M2023-08-15: 14.9M2023-08-31: 14.8M2023-09-15: 14.5M2023-09-29: 15.0M2023-10-13: 15.0M2023-10-31: 14.1M2023-11-15: 15.3M2023-11-30: 15.4M2023-12-15: 15.3M2023-12-29: 15.4M2024-01-12: 15.7M2024-01-31: 19.3M2024-02-15: 19.6M2024-02-29: 19.9M2024-03-15: 20.2M2024-03-28: 21.3M2024-04-15: 21.1M2024-04-30: 19.8M2024-05-15: 19.8M2024-05-31: 19.3M2024-06-14: 21.2M2024-06-28: 21.9M
the 28 Jun 2024 report24 earlier reportsnormal: 15.7M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Financials: Quarterly revenue change became public on 30 Jul 2024

Corcept Therapeutics reported revenue of $163.8M for the quarter ended 30 Jun 2024, 1.4× the same quarter last year.

This period
$163.8M (the quarter ended 30 Jun 2024)
Normal quarter (median of 8 earlier)
$111.7M
Typical spread (median absolute deviation)
$9.3M
How far from its usual level
+3.8
Same quarter last year
$117.7M
History used
4,657 days
2022-06-30: $103.4M2022-09-30: $101.7M2022-12-31: $103.1M2023-03-31: $105.7M2023-06-30: $117.7M2023-09-30: $123.6M2023-12-31: $135.4M2024-03-31: $146.8M2024-06-30: $163.8M
the quarter ended 30 Jun 20248 earlier quartersnormal: $111.7M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

7 May 2024confirmed

Confirmed across sources Institutional holdings and Filings + Financials and Short interest and volume

Corcept Therapeutics (CORT): had 21.3M shares sold short in the 28 Mar 2024 report, 1.2× the same report last year; it also reported revenue of $146.8M for the quarter ended 31 Mar 2024, 1.4× the same quarter last year; and it saw 47 13F filers open a new position in the quarter ended 31 Mar 2024, 1.5× the same quarter last year. Three unrelated kinds of activity within 35 days.

  • Short interest and volume: Short interest spike, became public on 10 Apr 2024
  • Financials: Quarterly revenue change, became public on 7 May 2024
  • Institutional holdings: Many funds opening a new position, became public on 15 May 2024
2023-03-31: 18.0M2023-04-14: 17.9M2023-04-28: 17.4M2023-05-15: 17.1M2023-05-31: 16.7M2023-06-15: 16.8M2023-06-30: 15.9M2023-07-14: 15.7M2023-07-31: 15.1M2023-08-15: 14.9M2023-08-31: 14.8M2023-09-15: 14.5M2023-09-29: 15.0M2023-10-13: 15.0M2023-10-31: 14.1M2023-11-15: 15.3M2023-11-30: 15.4M2023-12-15: 15.3M2023-12-29: 15.4M2024-01-12: 15.7M2024-01-31: 19.3M2024-02-15: 19.6M2024-02-29: 19.9M2024-03-15: 20.2M2024-03-28: 21.3M
The 28 Mar 2024 report against the 24 reports before it. this reportearliernormal: 15.7M
See the evidence (3 changes)

Short interest and volume: Short interest spike became public on 10 Apr 2024

Corcept Therapeutics had 21.3M shares sold short in the 28 Mar 2024 report, 1.2× the same report last year.

This period
21.3M (the 28 Mar 2024 report)
Normal report (median of 24 earlier)
15.7M
Typical spread (median absolute deviation)
965K
How far from its usual level
+3.6
Same report last year
18.0M
History used
2,281 days
2023-03-31: 18.0M2023-04-14: 17.9M2023-04-28: 17.4M2023-05-15: 17.1M2023-05-31: 16.7M2023-06-15: 16.8M2023-06-30: 15.9M2023-07-14: 15.7M2023-07-31: 15.1M2023-08-15: 14.9M2023-08-31: 14.8M2023-09-15: 14.5M2023-09-29: 15.0M2023-10-13: 15.0M2023-10-31: 14.1M2023-11-15: 15.3M2023-11-30: 15.4M2023-12-15: 15.3M2023-12-29: 15.4M2024-01-12: 15.7M2024-01-31: 19.3M2024-02-15: 19.6M2024-02-29: 19.9M2024-03-15: 20.2M2024-03-28: 21.3M
the 28 Mar 2024 report24 earlier reportsnormal: 15.7M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Financials: Quarterly revenue change became public on 7 May 2024

Corcept Therapeutics reported revenue of $146.8M for the quarter ended 31 Mar 2024, 1.4× the same quarter last year.

This period
$146.8M (the quarter ended 31 Mar 2024)
Normal quarter (median of 8 earlier)
$104.5M
Typical spread (median absolute deviation)
$6.8M
How far from its usual level
+4.0
Same quarter last year
$105.7M
History used
4,566 days
2022-03-31: $93.7M2022-06-30: $103.4M2022-09-30: $101.7M2022-12-31: $103.1M2023-03-31: $105.7M2023-06-30: $117.7M2023-09-30: $123.6M2023-12-31: $135.4M2024-03-31: $146.8M
the quarter ended 31 Mar 20248 earlier quartersnormal: $104.5M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Institutional holdings: Many funds opening a new position became public on 15 May 2024

Corcept Therapeutics saw 47 13F filers open a new position in the quarter ended 31 Mar 2024, 1.5× the same quarter last year.

This period
47 (the quarter ended 31 Mar 2024)
Normal quarter (median of 8 earlier)
31.5
Typical spread (median absolute deviation)
0.5
How far from its usual level
+4.9
Same quarter last year
32
History used
3,835 days
2022-03-31: 312022-06-30: 212022-09-30: 312022-12-31: 322023-03-31: 322023-06-30: 222023-09-30: 322023-12-31: 422024-03-31: 47
the quarter ended 31 Mar 20248 earlier quartersnormal: 31.5

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 17 Nov 2026several at once

    reported revenue of $340.5M for the quarter ended 30 Sep 2026, 1.6× the same quarter last year, while it saw 117 13F filers open a new position in the quarter ended 30 Sep 2026, 2.2× the same quarter last year. Two unrelated kinds of activity within 12 days.

    See the evidence (2 changes)

    Financials: Quarterly revenue change became public on 5 Nov 2026

    Corcept Therapeutics reported revenue of $340.5M for the quarter ended 30 Sep 2026, 1.6× the same quarter last year.

    This period
    $340.5M (the quarter ended 30 Sep 2026)
    Normal quarter (median of 8 earlier)
    $188.5M
    Typical spread (median absolute deviation)
    $16.4M
    How far from its usual level
    +6.3
    Same quarter last year
    $207.6M
    History used
    3,835 days
    2024-09-30: $182.5M2024-12-31: $181.9M2025-03-31: $157.2M2025-06-30: $194.4M2025-09-30: $207.6M2025-12-31: $202.1M2026-03-31: $164.9M2026-06-30: $256.1M2026-09-30: $340.5M
    the quarter ended 30 Sep 20268 earlier quartersnormal: $188.5M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Institutional holdings: Many funds opening a new position became public on 16 Nov 2026

    Corcept Therapeutics saw 117 13F filers open a new position in the quarter ended 30 Sep 2026, 2.2× the same quarter last year.

    This period
    117 (the quarter ended 30 Sep 2026)
    Normal quarter (median of 8 earlier)
    59.5
    Typical spread (median absolute deviation)
    7.5
    How far from its usual level
    +5.2
    Same quarter last year
    54
    History used
    4,748 days
    2024-09-30: 502024-12-31: 622025-03-31: 882025-06-30: 632025-09-30: 542025-12-31: 432026-03-31: 572026-06-30: 1172026-09-30: 117
    the quarter ended 30 Sep 20268 earlier quartersnormal: 59.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  2. 16 Nov 2026Institutional holdings change

    saw 117 13F filers open a new position in the quarter ended 30 Sep 2026, 2.2× the same quarter last year.

    Same quarter last year: 54; its normal quarter is 59.5.

    See the evidence
    This period
    117 (the quarter ended 30 Sep 2026)
    Normal quarter (median of 8 earlier)
    59.5
    Typical spread (median absolute deviation)
    7.5
    How far from its usual level
    +5.2
    Same quarter last year
    54
    History used
    4,748 days
    2024-09-30: 502024-12-31: 622025-03-31: 882025-06-30: 632025-09-30: 542025-12-31: 432026-03-31: 572026-06-30: 1172026-09-30: 117
    the quarter ended 30 Sep 20268 earlier quartersnormal: 59.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  3. 5 Nov 2026Financials change

    reported revenue of $340.5M for the quarter ended 30 Sep 2026, 1.6× the same quarter last year.

    Same quarter last year: $207.6M; its normal quarter is $188.5M.

    See the evidence
    This period
    $340.5M (the quarter ended 30 Sep 2026)
    Normal quarter (median of 8 earlier)
    $188.5M
    Typical spread (median absolute deviation)
    $16.4M
    How far from its usual level
    +6.3
    Same quarter last year
    $207.6M
    History used
    3,835 days
    2024-09-30: $182.5M2024-12-31: $181.9M2025-03-31: $157.2M2025-06-30: $194.4M2025-09-30: $207.6M2025-12-31: $202.1M2026-03-31: $164.9M2026-06-30: $256.1M2026-09-30: $340.5M
    the quarter ended 30 Sep 20268 earlier quartersnormal: $188.5M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  4. 23 Sep 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  5. 23 Sep 2026Filings record

    Director or officer change

  6. 28 May 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  7. 28 May 2026Filings record

    Director or officer change

  8. 20 Mar 2026Insiders record

    BAKER G LEONARD JR (director) bought 100,000 shares of CORT ($3.3M) (dated 19 Mar 2026)

  9. 14 Oct 2025Filings record

    A major agreement ended

  10. 6 Oct 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  11. 6 Oct 2025Filings record

    Director or officer change

  12. 15 May 2025Institutional holdings change

    saw 88 13F filers open a new position in the quarter ended 31 Mar 2025, 1.9× the same quarter last year.

    Same quarter last year: 47; its normal quarter is 37.

    See the evidence
    This period
    88 (the quarter ended 31 Mar 2025)
    Normal quarter (median of 8 earlier)
    37
    Typical spread (median absolute deviation)
    9
    How far from its usual level
    +3.8
    Same quarter last year
    47
    History used
    4,200 days
    2023-03-31: 322023-06-30: 222023-09-30: 322023-12-31: 422024-03-31: 472024-06-30: 292024-09-30: 502024-12-31: 622025-03-31: 88
    the quarter ended 31 Mar 20258 earlier quartersnormal: 37

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  13. 14 Nov 2024Institutional holdings change

    saw 50 13F filers open a new position in the quarter ended 30 Sep 2024, 1.6× the same quarter last year.

    Same quarter last year: 32; its normal quarter is 32.

    See the evidence
    This period
    50 (the quarter ended 30 Sep 2024)
    Normal quarter (median of 8 earlier)
    32
    Typical spread (median absolute deviation)
    2
    How far from its usual level
    +5.6
    Same quarter last year
    32
    History used
    4,018 days
    2022-09-30: 312022-12-31: 322023-03-31: 322023-06-30: 222023-09-30: 322023-12-31: 422024-03-31: 472024-06-30: 292024-09-30: 50
    the quarter ended 30 Sep 20248 earlier quartersnormal: 32

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  14. 30 Jul 2024several at once

    had 21.9M shares sold short in the 28 Jun 2024 report, 1.4× the same report last year, while it reported revenue of $163.8M for the quarter ended 30 Jun 2024, 1.4× the same quarter last year. Two unrelated kinds of activity within 28 days.

    See the evidence (3 changes)

    Short interest and volume: Short interest spike became public on 27 Jun 2024

    Corcept Therapeutics had 21.2M shares sold short in the 14 Jun 2024 report, 1.3× the same report last year.

    This period
    21.2M (the 14 Jun 2024 report)
    Normal report (median of 24 earlier)
    15.7M
    Typical spread (median absolute deviation)
    988K
    How far from its usual level
    +3.5
    Same report last year
    16.8M
    History used
    2,359 days
    2023-06-15: 16.8M2023-06-30: 15.9M2023-07-14: 15.7M2023-07-31: 15.1M2023-08-15: 14.9M2023-08-31: 14.8M2023-09-15: 14.5M2023-09-29: 15.0M2023-10-13: 15.0M2023-10-31: 14.1M2023-11-15: 15.3M2023-11-30: 15.4M2023-12-15: 15.3M2023-12-29: 15.4M2024-01-12: 15.7M2024-01-31: 19.3M2024-02-15: 19.6M2024-02-29: 19.9M2024-03-15: 20.2M2024-03-28: 21.3M2024-04-15: 21.1M2024-04-30: 19.8M2024-05-15: 19.8M2024-05-31: 19.3M2024-06-14: 21.2M
    the 14 Jun 2024 report24 earlier reportsnormal: 15.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 11 Jul 2024

    Corcept Therapeutics had 21.9M shares sold short in the 28 Jun 2024 report, 1.4× the same report last year.

    This period
    21.9M (the 28 Jun 2024 report)
    Normal report (median of 24 earlier)
    15.7M
    Typical spread (median absolute deviation)
    1.1M
    How far from its usual level
    +3.9
    Same report last year
    15.9M
    History used
    2,373 days
    2023-06-30: 15.9M2023-07-14: 15.7M2023-07-31: 15.1M2023-08-15: 14.9M2023-08-31: 14.8M2023-09-15: 14.5M2023-09-29: 15.0M2023-10-13: 15.0M2023-10-31: 14.1M2023-11-15: 15.3M2023-11-30: 15.4M2023-12-15: 15.3M2023-12-29: 15.4M2024-01-12: 15.7M2024-01-31: 19.3M2024-02-15: 19.6M2024-02-29: 19.9M2024-03-15: 20.2M2024-03-28: 21.3M2024-04-15: 21.1M2024-04-30: 19.8M2024-05-15: 19.8M2024-05-31: 19.3M2024-06-14: 21.2M2024-06-28: 21.9M
    the 28 Jun 2024 report24 earlier reportsnormal: 15.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Financials: Quarterly revenue change became public on 30 Jul 2024

    Corcept Therapeutics reported revenue of $163.8M for the quarter ended 30 Jun 2024, 1.4× the same quarter last year.

    This period
    $163.8M (the quarter ended 30 Jun 2024)
    Normal quarter (median of 8 earlier)
    $111.7M
    Typical spread (median absolute deviation)
    $9.3M
    How far from its usual level
    +3.8
    Same quarter last year
    $117.7M
    History used
    4,657 days
    2022-06-30: $103.4M2022-09-30: $101.7M2022-12-31: $103.1M2023-03-31: $105.7M2023-06-30: $117.7M2023-09-30: $123.6M2023-12-31: $135.4M2024-03-31: $146.8M2024-06-30: $163.8M
    the quarter ended 30 Jun 20248 earlier quartersnormal: $111.7M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  15. 30 Jul 2024Financials change

    reported revenue of $163.8M for the quarter ended 30 Jun 2024, 1.4× the same quarter last year.

    Same quarter last year: $117.7M; its normal quarter is $111.7M.

    See the evidence
    This period
    $163.8M (the quarter ended 30 Jun 2024)
    Normal quarter (median of 8 earlier)
    $111.7M
    Typical spread (median absolute deviation)
    $9.3M
    How far from its usual level
    +3.8
    Same quarter last year
    $117.7M
    History used
    4,657 days
    2022-06-30: $103.4M2022-09-30: $101.7M2022-12-31: $103.1M2023-03-31: $105.7M2023-06-30: $117.7M2023-09-30: $123.6M2023-12-31: $135.4M2024-03-31: $146.8M2024-06-30: $163.8M
    the quarter ended 30 Jun 20248 earlier quartersnormal: $111.7M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  16. 11 Jul 2024Short interest and volume change

    had 21.9M shares sold short in the 28 Jun 2024 report, 1.4× the same report last year.

    Same report last year: 15.9M; its normal report is 15.7M.

    See the evidence
    This period
    21.9M (the 28 Jun 2024 report)
    Normal report (median of 24 earlier)
    15.7M
    Typical spread (median absolute deviation)
    1.1M
    How far from its usual level
    +3.9
    Same report last year
    15.9M
    History used
    2,373 days
    2023-06-30: 15.9M2023-07-14: 15.7M2023-07-31: 15.1M2023-08-15: 14.9M2023-08-31: 14.8M2023-09-15: 14.5M2023-09-29: 15.0M2023-10-13: 15.0M2023-10-31: 14.1M2023-11-15: 15.3M2023-11-30: 15.4M2023-12-15: 15.3M2023-12-29: 15.4M2024-01-12: 15.7M2024-01-31: 19.3M2024-02-15: 19.6M2024-02-29: 19.9M2024-03-15: 20.2M2024-03-28: 21.3M2024-04-15: 21.1M2024-04-30: 19.8M2024-05-15: 19.8M2024-05-31: 19.3M2024-06-14: 21.2M2024-06-28: 21.9M
    the 28 Jun 2024 report24 earlier reportsnormal: 15.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  17. 27 Jun 2024Short interest and volume change

    had 21.2M shares sold short in the 14 Jun 2024 report, 1.3× the same report last year.

    Same report last year: 16.8M; its normal report is 15.7M.

    See the evidence
    This period
    21.2M (the 14 Jun 2024 report)
    Normal report (median of 24 earlier)
    15.7M
    Typical spread (median absolute deviation)
    988K
    How far from its usual level
    +3.5
    Same report last year
    16.8M
    History used
    2,359 days
    2023-06-15: 16.8M2023-06-30: 15.9M2023-07-14: 15.7M2023-07-31: 15.1M2023-08-15: 14.9M2023-08-31: 14.8M2023-09-15: 14.5M2023-09-29: 15.0M2023-10-13: 15.0M2023-10-31: 14.1M2023-11-15: 15.3M2023-11-30: 15.4M2023-12-15: 15.3M2023-12-29: 15.4M2024-01-12: 15.7M2024-01-31: 19.3M2024-02-15: 19.6M2024-02-29: 19.9M2024-03-15: 20.2M2024-03-28: 21.3M2024-04-15: 21.1M2024-04-30: 19.8M2024-05-15: 19.8M2024-05-31: 19.3M2024-06-14: 21.2M
    the 14 Jun 2024 report24 earlier reportsnormal: 15.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  18. 23 May 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  19. 23 May 2024Filings record

    Director or officer change

  20. 15 May 2024Institutional holdings change

    saw 47 13F filers open a new position in the quarter ended 31 Mar 2024, 1.5× the same quarter last year.

    Same quarter last year: 32; its normal quarter is 31.5.

    See the evidence
    This period
    47 (the quarter ended 31 Mar 2024)
    Normal quarter (median of 8 earlier)
    31.5
    Typical spread (median absolute deviation)
    0.5
    How far from its usual level
    +4.9
    Same quarter last year
    32
    History used
    3,835 days
    2022-03-31: 312022-06-30: 212022-09-30: 312022-12-31: 322023-03-31: 322023-06-30: 222023-09-30: 322023-12-31: 422024-03-31: 47
    the quarter ended 31 Mar 20248 earlier quartersnormal: 31.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  21. 7 May 2024several at once

    had 21.3M shares sold short in the 28 Mar 2024 report, 1.2× the same report last year; it also reported revenue of $146.8M for the quarter ended 31 Mar 2024, 1.4× the same quarter last year; and it saw 47 13F filers open a new position in the quarter ended 31 Mar 2024, 1.5× the same quarter last year. Three unrelated kinds of activity within 35 days.

    See the evidence (3 changes)

    Short interest and volume: Short interest spike became public on 10 Apr 2024

    Corcept Therapeutics had 21.3M shares sold short in the 28 Mar 2024 report, 1.2× the same report last year.

    This period
    21.3M (the 28 Mar 2024 report)
    Normal report (median of 24 earlier)
    15.7M
    Typical spread (median absolute deviation)
    965K
    How far from its usual level
    +3.6
    Same report last year
    18.0M
    History used
    2,281 days
    2023-03-31: 18.0M2023-04-14: 17.9M2023-04-28: 17.4M2023-05-15: 17.1M2023-05-31: 16.7M2023-06-15: 16.8M2023-06-30: 15.9M2023-07-14: 15.7M2023-07-31: 15.1M2023-08-15: 14.9M2023-08-31: 14.8M2023-09-15: 14.5M2023-09-29: 15.0M2023-10-13: 15.0M2023-10-31: 14.1M2023-11-15: 15.3M2023-11-30: 15.4M2023-12-15: 15.3M2023-12-29: 15.4M2024-01-12: 15.7M2024-01-31: 19.3M2024-02-15: 19.6M2024-02-29: 19.9M2024-03-15: 20.2M2024-03-28: 21.3M
    the 28 Mar 2024 report24 earlier reportsnormal: 15.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Financials: Quarterly revenue change became public on 7 May 2024

    Corcept Therapeutics reported revenue of $146.8M for the quarter ended 31 Mar 2024, 1.4× the same quarter last year.

    This period
    $146.8M (the quarter ended 31 Mar 2024)
    Normal quarter (median of 8 earlier)
    $104.5M
    Typical spread (median absolute deviation)
    $6.8M
    How far from its usual level
    +4.0
    Same quarter last year
    $105.7M
    History used
    4,566 days
    2022-03-31: $93.7M2022-06-30: $103.4M2022-09-30: $101.7M2022-12-31: $103.1M2023-03-31: $105.7M2023-06-30: $117.7M2023-09-30: $123.6M2023-12-31: $135.4M2024-03-31: $146.8M
    the quarter ended 31 Mar 20248 earlier quartersnormal: $104.5M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Institutional holdings: Many funds opening a new position became public on 15 May 2024

    Corcept Therapeutics saw 47 13F filers open a new position in the quarter ended 31 Mar 2024, 1.5× the same quarter last year.

    This period
    47 (the quarter ended 31 Mar 2024)
    Normal quarter (median of 8 earlier)
    31.5
    Typical spread (median absolute deviation)
    0.5
    How far from its usual level
    +4.9
    Same quarter last year
    32
    History used
    3,835 days
    2022-03-31: 312022-06-30: 212022-09-30: 312022-12-31: 322023-03-31: 322023-06-30: 222023-09-30: 322023-12-31: 422024-03-31: 47
    the quarter ended 31 Mar 20248 earlier quartersnormal: 31.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  22. 7 May 2024Financials change

    reported revenue of $146.8M for the quarter ended 31 Mar 2024, 1.4× the same quarter last year.

    Same quarter last year: $105.7M; its normal quarter is $104.5M.

    See the evidence
    This period
    $146.8M (the quarter ended 31 Mar 2024)
    Normal quarter (median of 8 earlier)
    $104.5M
    Typical spread (median absolute deviation)
    $6.8M
    How far from its usual level
    +4.0
    Same quarter last year
    $105.7M
    History used
    4,566 days
    2022-03-31: $93.7M2022-06-30: $103.4M2022-09-30: $101.7M2022-12-31: $103.1M2023-03-31: $105.7M2023-06-30: $117.7M2023-09-30: $123.6M2023-12-31: $135.4M2024-03-31: $146.8M
    the quarter ended 31 Mar 20248 earlier quartersnormal: $104.5M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  23. 10 Apr 2024Short interest and volume change

    had 21.3M shares sold short in the 28 Mar 2024 report, 1.2× the same report last year.

    Same report last year: 18.0M; its normal report is 15.7M.

    See the evidence
    This period
    21.3M (the 28 Mar 2024 report)
    Normal report (median of 24 earlier)
    15.7M
    Typical spread (median absolute deviation)
    965K
    How far from its usual level
    +3.6
    Same report last year
    18.0M
    History used
    2,281 days
    2023-03-31: 18.0M2023-04-14: 17.9M2023-04-28: 17.4M2023-05-15: 17.1M2023-05-31: 16.7M2023-06-15: 16.8M2023-06-30: 15.9M2023-07-14: 15.7M2023-07-31: 15.1M2023-08-15: 14.9M2023-08-31: 14.8M2023-09-15: 14.5M2023-09-29: 15.0M2023-10-13: 15.0M2023-10-31: 14.1M2023-11-15: 15.3M2023-11-30: 15.4M2023-12-15: 15.3M2023-12-29: 15.4M2024-01-12: 15.7M2024-01-31: 19.3M2024-02-15: 19.6M2024-02-29: 19.9M2024-03-15: 20.2M2024-03-28: 21.3M
    the 28 Mar 2024 report24 earlier reportsnormal: 15.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  24. 20 Feb 2024several at once

    saw 42 13F filers open a new position in the quarter ended 31 Dec 2023, 1.3× the same quarter last year, while it reported revenue of $135.4M for the quarter ended 31 Dec 2023, 1.3× the same quarter last year. Two unrelated kinds of activity on the same day.

    See the evidence (2 changes)

    Institutional holdings: Many funds opening a new position became public on 14 Feb 2024

    Corcept Therapeutics saw 42 13F filers open a new position in the quarter ended 31 Dec 2023, 1.3× the same quarter last year.

    This period
    42 (the quarter ended 31 Dec 2023)
    Normal quarter (median of 8 earlier)
    31
    Typical spread (median absolute deviation)
    1
    How far from its usual level
    +3.5
    Same quarter last year
    32
    History used
    3,744 days
    2021-12-31: 232022-03-31: 312022-06-30: 212022-09-30: 312022-12-31: 322023-03-31: 322023-06-30: 222023-09-30: 322023-12-31: 42
    the quarter ended 31 Dec 20238 earlier quartersnormal: 31

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Financials: Quarterly revenue change became public on 20 Feb 2024

    Corcept Therapeutics reported revenue of $135.4M for the quarter ended 31 Dec 2023, 1.3× the same quarter last year.

    This period
    $135.4M (the quarter ended 31 Dec 2023)
    Normal quarter (median of 8 earlier)
    $103.2M
    Typical spread (median absolute deviation)
    $3.4M
    How far from its usual level
    +3.1
    Same quarter last year
    $103.1M
    History used
    4,475 days
    2021-12-31: $98.8M2022-03-31: $93.7M2022-06-30: $103.4M2022-09-30: $101.7M2022-12-31: $103.1M2023-03-31: $105.7M2023-06-30: $117.7M2023-09-30: $123.6M2023-12-31: $135.4M
    the quarter ended 31 Dec 20238 earlier quartersnormal: $103.2M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  25. 20 Feb 2024Financials change

    reported revenue of $135.4M for the quarter ended 31 Dec 2023, 1.3× the same quarter last year.

    Same quarter last year: $103.1M; its normal quarter is $103.2M.

    See the evidence
    This period
    $135.4M (the quarter ended 31 Dec 2023)
    Normal quarter (median of 8 earlier)
    $103.2M
    Typical spread (median absolute deviation)
    $3.4M
    How far from its usual level
    +3.1
    Same quarter last year
    $103.1M
    History used
    4,475 days
    2021-12-31: $98.8M2022-03-31: $93.7M2022-06-30: $103.4M2022-09-30: $101.7M2022-12-31: $103.1M2023-03-31: $105.7M2023-06-30: $117.7M2023-09-30: $123.6M2023-12-31: $135.4M
    the quarter ended 31 Dec 20238 earlier quartersnormal: $103.2M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  26. 14 Feb 2024Institutional holdings change

    saw 42 13F filers open a new position in the quarter ended 31 Dec 2023, 1.3× the same quarter last year.

    Same quarter last year: 32; its normal quarter is 31.

    See the evidence
    This period
    42 (the quarter ended 31 Dec 2023)
    Normal quarter (median of 8 earlier)
    31
    Typical spread (median absolute deviation)
    1
    How far from its usual level
    +3.5
    Same quarter last year
    32
    History used
    3,744 days
    2021-12-31: 232022-03-31: 312022-06-30: 212022-09-30: 312022-12-31: 322023-03-31: 322023-06-30: 222023-09-30: 322023-12-31: 42
    the quarter ended 31 Dec 20238 earlier quartersnormal: 31

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  27. 25 May 2022Short interest and volume change

    had 20.3M shares sold short in the 13 May 2022 report, 2.1× the same report last year.

    Same report last year: 9.9M; its normal report is 9.9M.

    See the evidence
    This period
    20.3M (the 13 May 2022 report)
    Normal report (median of 24 earlier)
    9.9M
    Typical spread (median absolute deviation)
    1.8M
    How far from its usual level
    +3.8
    Same report last year
    9.9M
    History used
    1,596 days
    2021-04-30: 10.0M2021-05-14: 9.9M2021-05-28: 10.2M2021-06-15: 9.9M2021-06-30: 8.1M2021-07-15: 7.6M2021-07-30: 7.9M2021-08-13: 8.1M2021-08-31: 8.3M2021-09-15: 8.4M2021-09-30: 8.5M2021-10-15: 8.4M2021-10-29: 9.2M2021-11-15: 9.0M2021-11-30: 9.0M2021-12-15: 19.4M2022-01-14: 19.2M2022-01-31: 18.2M2022-02-15: 16.3M2022-02-28: 16.2M2022-03-15: 16.6M2022-03-31: 16.1M2022-04-14: 16.6M2022-04-29: 18.1M2022-05-13: 20.3M
    the 13 May 2022 report24 earlier reportsnormal: 9.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  28. 10 Mar 2022Short interest and volume change

    had 16.2M shares sold short in the 28 Feb 2022 report, 1.5× the same report last year.

    Same report last year: 10.8M; its normal report is 9.9M.

    See the evidence
    This period
    16.2M (the 28 Feb 2022 report)
    Normal report (median of 24 earlier)
    9.9M
    Typical spread (median absolute deviation)
    1.2M
    How far from its usual level
    +3.6
    Same report last year
    10.8M
    History used
    1,522 days
    2021-02-12: 10.8M2021-02-26: 10.8M2021-03-15: 10.8M2021-03-31: 10.5M2021-04-15: 10.6M2021-04-30: 10.0M2021-05-14: 9.9M2021-05-28: 10.2M2021-06-15: 9.9M2021-06-30: 8.1M2021-07-15: 7.6M2021-07-30: 7.9M2021-08-13: 8.1M2021-08-31: 8.3M2021-09-15: 8.4M2021-09-30: 8.5M2021-10-15: 8.4M2021-10-29: 9.2M2021-11-15: 9.0M2021-11-30: 9.0M2021-12-15: 19.4M2022-01-14: 19.2M2022-01-31: 18.2M2022-02-15: 16.3M2022-02-28: 16.2M
    the 28 Feb 2022 report24 earlier reportsnormal: 9.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  29. 26 Feb 2022Short interest and volume change

    had 16.3M shares sold short in the 15 Feb 2022 report, 1.5× the same report last year.

    Same report last year: 10.8M; its normal report is 9.9M.

    See the evidence
    This period
    16.3M (the 15 Feb 2022 report)
    Normal report (median of 24 earlier)
    9.9M
    Typical spread (median absolute deviation)
    1.2M
    How far from its usual level
    +3.7
    Same report last year
    10.8M
    History used
    1,509 days
    2021-01-29: 11.3M2021-02-12: 10.8M2021-02-26: 10.8M2021-03-15: 10.8M2021-03-31: 10.5M2021-04-15: 10.6M2021-04-30: 10.0M2021-05-14: 9.9M2021-05-28: 10.2M2021-06-15: 9.9M2021-06-30: 8.1M2021-07-15: 7.6M2021-07-30: 7.9M2021-08-13: 8.1M2021-08-31: 8.3M2021-09-15: 8.4M2021-09-30: 8.5M2021-10-15: 8.4M2021-10-29: 9.2M2021-11-15: 9.0M2021-11-30: 9.0M2021-12-15: 19.4M2022-01-14: 19.2M2022-01-31: 18.2M2022-02-15: 16.3M
    the 15 Feb 2022 report24 earlier reportsnormal: 9.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  30. 10 Feb 2022Short interest and volume change

    had 18.2M shares sold short in the 31 Jan 2022 report, 1.6× the same report last year.

    Same report last year: 11.3M; its normal report is 9.9M.

    See the evidence
    This period
    18.2M (the 31 Jan 2022 report)
    Normal report (median of 24 earlier)
    9.9M
    Typical spread (median absolute deviation)
    1.2M
    How far from its usual level
    +4.8
    Same report last year
    11.3M
    History used
    1,494 days
    2021-01-15: 11.8M2021-01-29: 11.3M2021-02-12: 10.8M2021-02-26: 10.8M2021-03-15: 10.8M2021-03-31: 10.5M2021-04-15: 10.6M2021-04-30: 10.0M2021-05-14: 9.9M2021-05-28: 10.2M2021-06-15: 9.9M2021-06-30: 8.1M2021-07-15: 7.6M2021-07-30: 7.9M2021-08-13: 8.1M2021-08-31: 8.3M2021-09-15: 8.4M2021-09-30: 8.5M2021-10-15: 8.4M2021-10-29: 9.2M2021-11-15: 9.0M2021-11-30: 9.0M2021-12-15: 19.4M2022-01-14: 19.2M2022-01-31: 18.2M
    the 31 Jan 2022 report24 earlier reportsnormal: 9.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  31. 27 Jan 2022Short interest and volume change

    had 19.2M shares sold short in the 14 Jan 2022 report, 1.6× the same report last year.

    Same report last year: 11.8M; its normal report is 9.9M.

    See the evidence
    This period
    19.2M (the 14 Jan 2022 report)
    Normal report (median of 24 earlier)
    9.9M
    Typical spread (median absolute deviation)
    1.2M
    How far from its usual level
    +5.3
    Same report last year
    11.8M
    History used
    1,477 days
    2020-12-31: 11.9M2021-01-15: 11.8M2021-01-29: 11.3M2021-02-12: 10.8M2021-02-26: 10.8M2021-03-15: 10.8M2021-03-31: 10.5M2021-04-15: 10.6M2021-04-30: 10.0M2021-05-14: 9.9M2021-05-28: 10.2M2021-06-15: 9.9M2021-06-30: 8.1M2021-07-15: 7.6M2021-07-30: 7.9M2021-08-13: 8.1M2021-08-31: 8.3M2021-09-15: 8.4M2021-09-30: 8.5M2021-10-15: 8.4M2021-10-29: 9.2M2021-11-15: 9.0M2021-11-30: 9.0M2021-12-15: 19.4M2022-01-14: 19.2M
    the 14 Jan 2022 report24 earlier reportsnormal: 9.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  32. 28 Dec 2021Short interest and volume change

    had 19.4M shares sold short in the 15 Dec 2021 report, 1.5× the same report last year.

    Same report last year: 12.9M; its normal report is 9.9M.

    See the evidence
    This period
    19.4M (the 15 Dec 2021 report)
    Normal report (median of 24 earlier)
    9.9M
    Typical spread (median absolute deviation)
    1.2M
    How far from its usual level
    +5.5
    Same report last year
    12.9M
    History used
    1,447 days
    2020-12-15: 12.9M2020-12-31: 11.9M2021-01-15: 11.8M2021-01-29: 11.3M2021-02-12: 10.8M2021-02-26: 10.8M2021-03-15: 10.8M2021-03-31: 10.5M2021-04-15: 10.6M2021-04-30: 10.0M2021-05-14: 9.9M2021-05-28: 10.2M2021-06-15: 9.9M2021-06-30: 8.1M2021-07-15: 7.6M2021-07-30: 7.9M2021-08-13: 8.1M2021-08-31: 8.3M2021-09-15: 8.4M2021-09-30: 8.5M2021-10-15: 8.4M2021-10-29: 9.2M2021-11-15: 9.0M2021-11-30: 9.0M2021-12-15: 19.4M
    the 15 Dec 2021 report24 earlier reportsnormal: 9.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  33. 12 Aug 2021Filings record

    Director or officer change

  34. 16 Jun 2021Insiders record

    BAKER G LEONARD JR (director) bought 150,000 shares of CORT ($3.2M) (dated 15 Jun 2021)

  35. 10 Jun 2021Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  36. 10 Jun 2021Filings record

    Director or officer change

  37. 1 Mar 2021Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  38. 1 Mar 2021Filings record

    Director or officer change

  39. 3 Dec 2020Insiders record

    BAKER G LEONARD JR (director) bought 1,177 shares of CORT ($26,825) (dated 2 Dec 2020)

  40. 1 Dec 2020Insiders record

    BAKER G LEONARD JR (director) bought 361 shares of CORT ($8,234) (dated 30 Nov 2020)

Showing the newest 40 of 71 entries; narrow the window or the kind of data to see older ones.

Not listed: 367 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001088856
Ticker
CORT
Domain
corcept.com
Employer name
Corcept Therapeutics, Inc. (1 unverified)
Hq location
CA|REDWOOD CITY|94065 (1 unverified)
Name
Corcept Therapeutics Inc.
Uei
MMA8PS1NF6M8
Wikidata
Q15734041
Wikipedia
Corcept Therapeutics
  • DOL H-1B labor condition applications and PERM certifications97 data points10 Jan 2022 to 14 Sep 2026
  • SEC Form 13F institutional holdings481 data points30 Jun 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)135 records28 Jan 2016 to 3 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)1138 data points31 Dec 1999 to 22 Oct 2026
  • SEC Form 4 insider transactions266 records, 740 data points6 Jan 2016 to 17 Nov 2026
  • FINRA short interest (twice monthly)636 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
  • USASpending.gov federal awards48 data points20 Mar 2012 to 21 Mar 2019
  • Wikipedia pageviews2882 data points1 Jan 2019 to 21 Nov 2026